HRH3 and multiple sclerosis: Uncontrolled histamine release in various immunopathological conditions where the brain tissue represents the site of pathogenetic events may support the utility of pharmacological targeting of H3R via receptor agonists to prevent the development of tissue lesions either in multiple sclerosis or during CM.